Clinical Trial Update: Daratumumab for Polyneuropathy Associated With MGUS [Phase 2]

View source ↗

Summary

A Phase 2 trial of daratumumab for polyneuropathy associated with monoclonal gammopathy of undetermined significance has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Undetermined Significance
• Peripheral Neuropathy

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Georgetown University | Conditions: Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Status: WITHDRAWN